# Medicine's Monopoly Problem
Pharmaceutical monopolies restrict consumer access to medications and inflate drug prices through patent protections and regulatory barriers that federal law enables. The healthcare industry operates under antitrust exemptions and intellectual property rules that allow manufacturers to maintain exclusive control over life-saving treatments long after initial development costs recover.
Patent law grants pharmaceutical companies extended market exclusivity periods under the Patent Term Extension provisions codified in 35 U.S.C. Section 156. This framework extends patent life beyond the standard 20-year term from filing, permitting manufacturers to charge monopoly prices without generic competition. The FDA's approval process itself creates additional barriers through regulatory exclusivity periods under the Federal Food, Drug, and Cosmetic Act, which prevent generic alternatives from entering the market for defined periods even after patents expire.
Evergreening strategies allow companies to modify formulations slightly and obtain new patents, resetting exclusivity clocks without substantive innovation. Companies file continuation patents and reformulation claims that create patent thickets around existing drugs, blocking generic manufacturers from market entry despite the underlying discovery's age.
The FTC has challenged several anticompetitive pharmaceutical settlements where brand-name manufacturers paid generic competitors to delay market entry. However, these enforcement actions remain sporadic. Pay-for-delay agreements under antitrust law constitute illegal monopolization under Section 2 of the Sherman Act, yet the practice persists across the industry.
Biosimilar pathways created by the Biologics Price Competition and Innovation Act theoretically increased competition for biologic drugs. Yet manufacturers exploit loopholes through product hopping and strategic marketing to prevent biosimilar adoption.
Congress could strengthen antitrust enforcement, shorten patent terms, or eliminate evergreening through legislative action. International reference pricing would link U.S. drug costs to lower prices in other developed nations, though pharmaceutical lobbies fiercely oppose such measures. The